Burkitt’s lymphoma refractory – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:22:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Burkitt’s lymphoma refractory – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers https://clinicaltrials.eu/trial/a-study-testing-the-safety-of-cd19-targeted-car-t-cell-therapy-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-cancers/ Wed, 29 Apr 2026 15:08:31 +0000 https://clinicaltrials.eu/trial/a-study-testing-the-safety-of-cd19-targeted-car-t-cell-therapy-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-cancers/ This study is looking at two types of cancer that affect certain white blood cells. The first is B-cell precursor ALL, which is a cancer where the bone marrow makes too many immature white blood cells. The second is B-cell Non Hodgkin Lymphoma, which is a cancer that starts in white blood cells called lymphocytes and can affect lymph nodes and other parts of the body. Both of these cancers have either come back after previous treatment or have not responded to treatment. The study will use a treatment called MB-huCART19.1, which is a type of therapy where a patient’s own immune cells are collected and modified in a laboratory to better recognize and attack cancer cells that have a specific marker called CD19 on their surface. These modified cells, known as CAR T-cells, are then given back to the patient through intravenous infusion, which means the cells are delivered directly into a vein.

The purpose of this study is to find out the safest dose of these modified cells that can be given to patients and to see how well the treatment works. The study will look at how many patients experience serious side effects within 28 days after receiving the treatment, which will help determine the best dose to use in the next part of the study. The study will also measure how well the treatment works by checking if the cancer responds to the treatment and how long patients remain free from disease.

During the study, patients will first have their own immune cells collected. These cells will then be modified in a laboratory to target the cancer cells. Before receiving the modified cells back, patients may receive chemotherapy to prepare their body for the treatment. After the modified cells are given through an infusion into a vein, patients will be monitored closely for side effects and to see how well the treatment is working. The study will follow patients for up to 12 months to track their progress and see if the cancer comes back. This study is for children and young adults between 1 and 45 years of age who have tried other treatments that did not work or who cannot receive other standard treatments.

]]> Study on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma https://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-or-refractory-burkitt-lymphoma/ Wed, 29 Apr 2026 14:24:51 +0000 https://clinicaltrials.eu/trial/study-on-brexucabtagene-autoleucel-for-adults-with-relapsed-or-refractory-burkitt-lymphoma/ This clinical trial is focused on studying a rare type of cancer called Burkitt Lymphoma, which is a form of B-cell malignancy. The treatment being tested is called brexucabtagene autoleucel, also known by its code name KTE-X19. This treatment is a type of cell therapy that involves modifying a patient’s own T cells to help them fight cancer. The purpose of the study is to evaluate how effective this treatment is in patients with relapsed or refractory Burkitt Lymphoma, meaning the cancer has returned or did not respond to previous treatments.

Participants in the study will receive the treatment through an intravenous infusion, which means it is delivered directly into the bloodstream. The study will monitor the response of the cancer to the treatment, looking for signs of improvement such as a reduction in the size of the cancer or complete disappearance. The study will also track how long any positive effects last and the overall survival of participants. The trial is designed to gather information over a period of time to understand the benefits and any potential risks associated with the treatment.

In addition to the main treatment, other medications may be used to support the participants during the trial. These include dexamethasone, a corticosteroid that helps reduce inflammation, and mesna, which is used to protect the bladder from harmful effects of certain chemotherapy drugs. The study aims to provide valuable insights into the potential of brexucabtagene autoleucel as a treatment option for those with Burkitt Lymphoma, offering hope for improved outcomes in this challenging condition.

]]>